Expanded Access Use of Tucatinib for HER2+ Metastatic Breast Cancer

Trial Profile

Expanded Access Use of Tucatinib for HER2+ Metastatic Breast Cancer

Suspended
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 05 Apr 2018

At a glance

  • Drugs Tucatinib (Primary)
  • Indications Breast cancer
  • Focus Expanded access; Therapeutic Use
  • Sponsors Cascadian Therapeutics
  • Most Recent Events

    • 30 Mar 2018 Status changed from recruiting to suspended.
    • 09 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top